Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Mesoblast Ltd

MESO Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017โ€“FY2026

Last close ยท Oct 23, 2026

$12.28

2.2%
Compare
Revenue Total sales reported in the income statement.
$120M
599.2% vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$57.5M
Free cash flow Cash from operations minus capital spending.
โˆ’$44.7M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$1.6B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$0.44 EPS (TTM)

What Mesoblast Ltd does

No business description yet.

Legal name
MESOBLAST LTD
Fiscal year ends
June 30, 2026
Latest annual report
20-F ยท Aug 27, 2026
Accession ยท CIK
0001345099-26-000081
0001345099

Revenue and margins

Mesoblast Ltd had $120M of revenue in fiscal 2026, up 599.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$44.7M in fiscal 2026, โˆ’37.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Mesoblast Ltd returned โ€” to shareholders in fiscal 2026. The diluted share count rose 7.2%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Mesoblast Ltd can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $60.4M$71.3M$63.0M$162M$103M
Debt incl. finance leases $96.6M$109M$114M$122M$119M
Debt / equity 0.2x0.2x0.2x0.2x0.2x
Current ratio 1.4x1.9x1.2x2.0x2.4x
Quick ratio 1.4x1.9x1.2x1.8x2.1x
Total assets $662M$669M$669M$785M$773M
Total liabilities $165M$168M$189M$187M$205M
Shareholders' equity $497M$502M$480M$597M$568M
Net debt (โˆ’ = net cash) $36.2M$37.4M$51.4Mโˆ’$39.7M$16.3M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ“ โœ• โœ“ โœ• โœ• โœ“ โœ• โœ“ โœ“
Cash from operations exceeds net income โœ• โœ• โœ“ โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โœ• โœ• โœ“ โœ• โœ• โœ• โœ• โœ“ โœ“
Current ratio rose โ€” โœ“ โœ• โœ“ โœ“ โœ• โœ“ โœ• โœ“ โœ“
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โœ• โœ• โœ“
Revenue rose relative to assets โ€” โœ“ โœ“ โœ“ โœ• โœ“ โœ• โœ• โœ“ โœ“
F-score โ€” / 33 / 82 / 85 / 81 / 82 / 83 / 81 / 95 / 96 / 9
Accruals ratio 2.8%5.9%โˆ’4.8%โˆ’4.0%0.3%โˆ’3.6%โˆ’2.8%โˆ’5.9%โˆ’7.2%โˆ’1.8%
Altman Z'' โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $2.4M $17.3M $16.7M $32.2M $7.4M $10.2M $7.5M $5.9M $17.2M $120M
Gross profit โ€” โ€” โ€” โ€” โ€” โ€” $7.5M $5.9M $12.1M $104M
Research and development $58.9M $65.9M $59.8M $56.2M $53.0M $32.8M $52.8M $39.7M $34.8M $97.5M
Interest expense โ€” $1.8M $11.7M $14.7M $15.9M $16.9M $19.4M $20.7M $21.8M $19.9M
Pretax income โˆ’$90.2M โˆ’$66.0M โˆ’$98.8M โˆ’$87.4M โˆ’$99.6M โˆ’$91.6M โˆ’$82.1M โˆ’$88.1M โˆ’$102M โˆ’$56.9M
Income tax โˆ’$13.4M โˆ’$30.7M โˆ’$9.0M โˆ’$9.4M โˆ’$0.8M โˆ’$0.2M โˆ’$0.2M โˆ’$0.2M $0.3M $0.6M
Net income โˆ’$76.8M โˆ’$35.3M โˆ’$89.8M โˆ’$77.9M โˆ’$98.8M โˆ’$91.3M โˆ’$81.9M โˆ’$88.0M โˆ’$102M โˆ’$57.5M
Net income to common โˆ’$76.8M โˆ’$35.3M โˆ’$89.8M โˆ’$77.9M โˆ’$98.8M โˆ’$91.3M โˆ’$81.9M โˆ’$88.0M โˆ’$102M โˆ’$57.5M
Diluted EPS โˆ’$1.93 โˆ’$0.76 โˆ’$1.82 โˆ’$1.47 โˆ’$1.63 โˆ’$1.34 โˆ’$1.05 โˆ’$0.89 โˆ’$0.85 โˆ’$0.44
Diluted shares 0.04B 0.05B 0.05B 0.05B 0.06B 0.07B 0.08B 0.10B 0.12B 0.13B
Cash flow
Cash from operations โˆ’$95.5M โˆ’$75.0M โˆ’$57.8M โˆ’$50.4M โˆ’$101M โˆ’$65.8M โˆ’$63.3M โˆ’$48.5M โˆ’$50.0M โˆ’$43.8M
Capital expenditure โ€” โ€” โ€” โ€” โ€” โ€” $0.3M $0.3M $0.7M $0.8M
Free cash flow โ€” โ€” โ€” โ€” โ€” โ€” โˆ’$63.5M โˆ’$48.7M โˆ’$50.6M โˆ’$44.7M
Depreciation and amortization $3.1M $2.7M $2.1M $3.7M $4.3M $4.4M $4.1M $4.7M $2.5M $2.5M
Stock-based compensation $5.3M $6.2M $4.4M $7.5M $12.5M $5.5M $3.7M $5.9M $22.1M $14.9M
Balance sheet
Cash and short-term investments $45.8M $37.8M $50.4M $129M $137M $60.4M $71.3M $63.0M $162M $103M
Total debt $0.0M $59.4M $81.3M $89.5M $94.2M $96.6M $109M $114M $122M $119M
Current assets $63.6M $101M $62.5M $137M $148M $69.8M $81.7M $86.5M $204M $197M
Current liabilities $36.7M $24.0M $44.3M $90.1M $94.3M $51.4M $42.0M $73.2M $103M $81.1M
Inventory โ€” โ€” โ€” โ€” โ€” โ€” โ€” $0.0M $22.2M $28.1M
Property and equipment, net $1.8M $1.1M $0.8M $2.3M $3.0M $2.0M $1.4M $1.1M $1.7M $1.8M
Total assets $656M $692M $652M $734M $745M $662M $669M $669M $785M $773M
Total liabilities $139M $146M $171M $184M $163M $165M $168M $189M $187M $205M
Shareholders' equity $517M $546M $481M $549M $581M $497M $502M $480M $597M $568M
Margins
Gross margin โ€” โ€” โ€” โ€” โ€” โ€” 100.0% 100.0% 70.2% 86.1%
Net margin โˆ’3,184.7% โˆ’203.5% โˆ’537.0% โˆ’242.4% โˆ’1,329.2% โˆ’894.6% โˆ’1,091.7% โˆ’1,490.3% โˆ’593.9% โˆ’47.8%
FCF margin โ€” โ€” โ€” โ€” โ€” โ€” โˆ’847.0% โˆ’825.6% โˆ’294.4% โˆ’37.1%
Returns
Return on equity โˆ’14.9% โˆ’6.6% โˆ’17.5% โˆ’15.1% โˆ’17.5% โˆ’16.9% โˆ’16.4% โˆ’17.9% โˆ’19.0% โˆ’9.9%
Return on assets โˆ’11.7% โˆ’5.2% โˆ’13.4% โˆ’11.2% โˆ’13.4% โˆ’13.0% โˆ’12.3% โˆ’13.1% โˆ’14.1% โˆ’7.4%
Return on tangible equity โˆ’14.9% โˆ’6.5% โˆ’18.7% โˆ’14.2% โˆ’17.0% โˆ’18.4% โˆ’16.3% โˆ’18.3% โˆ’17.1% โˆ’10.1%
Growth
Revenue growth โ€” 618.9% โˆ’3.6% 92.3% โˆ’76.9% 37.4% โˆ’26.5% โˆ’21.3% 191.4% 599.2%
Share count change โ€” 16.7% 6.2% 7.0% 14.4% 12.9% 13.9% 26.9% 22.4% 7.2%
Financial health
Debt / equity 0.0x 0.1x 0.2x 0.2x 0.2x 0.2x 0.2x 0.2x 0.2x 0.2x
Current ratio 1.7x 4.2x 1.4x 1.5x 1.6x 1.4x 1.9x 1.2x 2.0x 2.4x
Quick ratio 1.7x 4.2x 1.4x 1.5x 1.6x 1.4x 1.9x 1.2x 1.8x 2.1x
Capital allocation
Capex / revenue โ€” โ€” โ€” โ€” โ€” โ€” 3.5% 4.6% 4.0% 0.7%
Stock comp / revenue 218.7% 35.7% 26.1% 23.4% 168.3% 54.2% 48.7% 99.5% 128.4% 12.4%
Quality scores
Piotroski F-score โ€” 3.0 2.0 5.0 1.0 2.0 3.0 1.0 5.0 6.0
Accruals ratio 2.8% 5.9% โˆ’4.8% โˆ’4.0% 0.3% โˆ’3.6% โˆ’2.8% โˆ’5.9% โˆ’7.2% โˆ’1.8%

Source: SEC EDGAR XBRL filings (CIK 0001345099). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 10 ordinary shares). For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open